ZA200905101B - Diagosis and treatment of preeclampsia - Google Patents

Diagosis and treatment of preeclampsia

Info

Publication number
ZA200905101B
ZA200905101B ZA2009/05101A ZA200905101A ZA200905101B ZA 200905101 B ZA200905101 B ZA 200905101B ZA 2009/05101 A ZA2009/05101 A ZA 2009/05101A ZA 200905101 A ZA200905101 A ZA 200905101A ZA 200905101 B ZA200905101 B ZA 200905101B
Authority
ZA
South Africa
Prior art keywords
diagosis
preeclampsia
treatment
Prior art date
Application number
ZA2009/05101A
Other languages
English (en)
Inventor
Stefan Hansson
Bo Akerstrom
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of ZA200905101B publication Critical patent/ZA200905101B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
ZA2009/05101A 2007-02-12 2009-07-21 Diagosis and treatment of preeclampsia ZA200905101B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Publications (1)

Publication Number Publication Date
ZA200905101B true ZA200905101B (en) 2012-01-25

Family

ID=39295873

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/05101A ZA200905101B (en) 2007-02-12 2009-07-21 Diagosis and treatment of preeclampsia

Country Status (18)

Country Link
US (3) US8568999B2 (enExample)
EP (3) EP2111555B1 (enExample)
JP (2) JP5604111B2 (enExample)
KR (2) KR101454013B1 (enExample)
AU (1) AU2008214837B2 (enExample)
BR (1) BRPI0808340A2 (enExample)
CA (1) CA2674204C (enExample)
DK (2) DK2614832T3 (enExample)
EA (2) EA031877B1 (enExample)
ES (2) ES2426069T3 (enExample)
HR (2) HRP20130809T1 (enExample)
HU (1) HUE031613T2 (enExample)
MX (2) MX347788B (enExample)
NZ (1) NZ578077A (enExample)
PL (2) PL2614832T3 (enExample)
PT (2) PT2614832T (enExample)
WO (1) WO2008098734A1 (enExample)
ZA (1) ZA200905101B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ578077A (en) * 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin
DK2313106T3 (en) 2008-07-18 2016-07-25 A1M Pharma Ab MEDICAL USE OF RADICAL binder and the antioxidant is alpha-1-microglobulin
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
PT2550535E (pt) * 2010-03-24 2015-09-07 Preelumina Diagnostics Ab Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia
WO2011125877A1 (ja) * 2010-03-31 2011-10-13 積水メディカル株式会社 イムノクロマトグラフィーを利用した測定方法、イムノクロマトグラフィー用テストストリップ及びイムノクロマトグラフィー用測定試薬キット
EP2766726A1 (en) 2011-10-14 2014-08-20 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
PL2900254T3 (pl) * 2012-09-05 2017-02-28 A1M Pharma Ab Alfa-1 mikroglobulina do użycia w leczeniu chorób związanych z mitochondriami
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
KR20170125975A (ko) 2015-03-16 2017-11-15 에이원엠 파마 에이비 자간전증에 대한 바이오마커
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
WO2017096405A1 (en) 2015-12-04 2017-06-08 Nx Prenatal Inc. Use of circulating microparticles to stratify risk of spontaneous preterm birth
US11054389B2 (en) * 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
WO2024053586A1 (ja) * 2022-09-05 2024-03-14 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体
KR20250145250A (ko) * 2024-03-28 2025-10-13 계명대학교 산학협력단 Ccl20 및 csf3 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 태아성장제한 진단용 바이오마커 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
DE60219642T2 (de) 2001-09-04 2008-01-17 Iq Corp. B.V. Bestimung und quantifizierung von erythrocytenpopulation in proben
JPWO2003083479A1 (ja) * 2002-03-29 2005-08-04 松下電器産業株式会社 血液処理方法、血液処理デバイス、ヘモグロビン類測定方法およびヘモグロビン類測定デバイス
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
WO2005002515A2 (en) * 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
WO2005051379A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
JP2009524031A (ja) 2006-01-18 2009-06-25 ヴィック、イミュノロジッシェ ダイアグノステック ウー．ベラートゥング カーゲー シリコンに接着するポリペプチドおよび細胞を分析するための試験系
NZ578077A (en) 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
DK2313106T3 (en) 2008-07-18 2016-07-25 A1M Pharma Ab MEDICAL USE OF RADICAL binder and the antioxidant is alpha-1-microglobulin
PT2550535E (pt) 2010-03-24 2015-09-07 Preelumina Diagnostics Ab Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia

Also Published As

Publication number Publication date
PT2614832T (pt) 2016-10-18
JP5792772B2 (ja) 2015-10-14
MX347788B (es) 2017-05-12
PT2111555E (pt) 2013-09-04
EA201500335A1 (ru) 2016-08-31
NZ578077A (en) 2012-04-27
KR20140095572A (ko) 2014-08-01
HUE031613T2 (en) 2017-09-28
EP2614832B1 (en) 2016-07-13
JP2014012670A (ja) 2014-01-23
PL2111555T3 (pl) 2013-10-31
DK2614832T3 (da) 2016-10-31
EA200970758A1 (ru) 2010-02-26
EA022609B1 (ru) 2016-02-29
KR101608501B1 (ko) 2016-04-04
KR20100015315A (ko) 2010-02-12
US20180284087A1 (en) 2018-10-04
WO2008098734A1 (en) 2008-08-21
AU2008214837B2 (en) 2013-01-10
CA2674204C (en) 2017-07-11
EP2614832A1 (en) 2013-07-17
EP2111555B1 (en) 2013-05-29
DK2111555T3 (da) 2013-09-02
CA2674204A1 (en) 2008-08-21
US20140065170A1 (en) 2014-03-06
AU2008214837A1 (en) 2008-08-21
EP2111555A1 (en) 2009-10-28
BRPI0808340A2 (pt) 2017-05-30
US20100105070A1 (en) 2010-04-29
EA031877B1 (ru) 2019-03-29
EP2613150A1 (en) 2013-07-10
US10359406B2 (en) 2019-07-23
JP2010518386A (ja) 2010-05-27
HRP20130809T1 (xx) 2013-10-11
KR101454013B1 (ko) 2014-11-12
US8568999B2 (en) 2013-10-29
HRP20161266T1 (hr) 2016-12-16
ES2599003T3 (es) 2017-01-31
PL2614832T3 (pl) 2017-01-31
JP5604111B2 (ja) 2014-10-08
ES2426069T3 (es) 2013-10-21
MX2009008408A (es) 2009-11-02

Similar Documents

Publication Publication Date Title
PL2614832T3 (pl) Diagnostyka i leczenie stanu przedrzucawkowego
ZA201003625B (en) 5-anilinoimidazopyridines and methods of use
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
GB0610867D0 (en) Treatment of pain
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
EP2191458A4 (en) FINGER-FITTED DEVICES AND METHODS OF USE THEREOF
IL209754A0 (en) Diazacarbazoles and methods of use
IL206125A0 (en) Azaindolizines and methods of use
IL193748A0 (en) Treatment of pain
ZA200904806B (en) Prevention and treatment of sub-clinical pcvd
GB0719577D0 (en) Microimplant devices and methods of making and use thereof
IL209548A0 (en) Diazacarbazoles and methods of use
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
GB0807018D0 (en) Antibodies and treatment
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
ZA201000225B (en) Treatment of depression
GB0708452D0 (en) Treatment of nuclear studge
EP2180894A4 (en) METHOD OF ACTIVATING IRS-1 AND ACT
EP2164494A4 (en) Methods of Treatment
EP2512504A4 (en) COMPOSITION AND THERAPEUTIC METHOD
GB0723100D0 (en) Treatment of HFnEF
GB0610868D0 (en) Treatment of pain
GB0714500D0 (en) composition and treatment
EP2203432A4 (en) PROCESSING METHOD
GB0616450D0 (en) Treatment of pain